Predicton of resistance or sensitivity to oncolytic virus studied by gene expression profile in vitro on cancer cells
November 2016
Pusan National University, Yangsan, South Korea(1)
SillaJen, Inc., Busan, South Korea(2)
SillaJen, Inc., Busan, South Korea(2)
Oncolytic viruses (OVs) mediate tumor regression through selective replication in, and lysis of, tumor cells and induction of systemic anti-tumor immunity without damage to normal cells. Pexa-Vec is a cancer-specific and transgene-inserted oncolytic and immunotherapeutic vaccinia virus. As far as now, no studies have used Pexa-Vec to treat hematologic malignancies. In the present study, the researchers investigate the oncolytic effects of Pexa-Vec in vitro against lymphoid or myeloid cancer cell lines. Gene expression analyses were also conducted to determine the possible predictive gene changes in Pexa-Vec resistant cells compared with sensitive cells. These changes may enable clarify the characteristics of cancers resistant to Pexa-Vec. Interestingly, lymphoid malignant cells were shown to be resistant to Pexa-Vec and displayed up-regulated genes associated with resistance to oncolytic viral therapy. These data provide potential targets to overcome resistance and suggest that molecular assays may be useful in selecting patients for further clinical trials with Pexa-Vec.
Gene expression profiling of hematologic malignant cell lines resistant to oncolytic virus treatment
Tae-Ho Hwang(1), Hyuk-Chan Kwon(2)
Added on: 09-19-2021
[1] https://www.oncotarget.com/article/13598/text/[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
